A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: He Huang, MD
- Phone Number: 057187233772
- Email: hehuangyu@126.com
Study Contact Backup
- Name: Yongxian Hu, MD
- Phone Number: 057187233772
- Email: huyongxian2000@aliyun.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The first affiliated hospital of medical college of zhejiang university
-
Contact:
- He Huang, MD
- Phone Number: 057187233772
- Email: hehuangyu@126.com
-
Contact:
- Yongxian Hu, MD
- Phone Number: 057187233772
- Email: huyongxian2000@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Male or female, age ≥ 18 years old;
- 2. CAR-T cells can be prepared normally, or who have failed to prepare autologous CAR-T cells (including the number of autologous lymphocytes <1×10^9 or the expansion during the preparation process is insufficient or cannot reinfusion);
- 3. Patients diagnosed with CD33 positive acute myeloid leukemia (AML) through histological or immunological examination,and CD33 positive expression rate >80%;
- 4. Complies with the 2016 WHO classification for AML diagnosis and meets the diagnostic criteria for recurrence and refractory acute myeloid leukemia in the "Chinese Guidelines for the Diagnosis and Treatment of relapsed and refractory acute myeloid leukemia (2017 edition)", and currently there are no clinically relevant treatments or suitable clinical trials for registration:
- a) Diagnostic criteria for recurrent AML: After complete remission (CR), leukemia cells reappear in peripheral blood or primitive cells in bone marrow>0.050 (excluding other reasons such as bone marrow regeneration after consolidation chemotherapy) or leukemia cell infiltration appears outside the bone marrow;
- b) Diagnostic criteria for refractory AML: initial treatment cases that have failed to respond to two courses of standard protocol treatment; Patients who relapse within 12 months after consolidation and intensive treatment after CR; Patients who relapse after 12 months but fail conventional chemotherapy; Patients with 2 or more relapses; Persistent extramedullary leukemia;
- 5. The number of primitive cells (promyelocytes and/or promyelocytes) in the bone marrow > 5% (morphology) and/or > 1% (flow cytometry detection);
- 6. Total bilirubin ≤ 51 μmol / L, ALT and AST ≤ 3 times of the upper limit of normal value, serum creatinine ≤ 176.8 μmol / L;
- 7. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%;
- 8. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%;
- 9. The estimated survival time is more than 3 months;
- 10. ECOG score was 0-2;
- 11. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
- 12. Those who voluntarily participated in this trial and provided informed consent;
Exclusion Criteria:
- 1. Patients with the history of epilepsy or other CNS disease;
- 2. Patients with prolonged QT interval time or severe heart disease;
- 3. Active infection with no cure;
- 4. Active infection of hepatitis B virus or C virus ;
- 5. Before using any gene therapy products;
- 6. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
- 7. Suffering from other uncontrolled diseases that the researchers consider unsuitable for joining;
- 8. Infected with AIDS virus;
- 9. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CAR-T cells( chimeric antigen receptor T cells)
Dose escalation follows the standard 3+3 dose escalation design.
A total of 3 dose levels are set for subjects.
|
Each subject receive CD33 CAR T-cells by intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 2 years after Treatment
|
Incidence of treatment-emergent adverse events [Safety and Tolerability]
|
Up to 2 years after Treatment
|
|
Dose-limiting toxicity (DLT)
Time Frame: Up to 28 days after Treatment
|
Adverse events assessed according to NCI-CTCAE v5.0 criteria
|
Up to 28 days after Treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival, OS
Time Frame: Up to 1 years after CAR-T infusion
|
The time from CAR-T infusion to death due to any cause
|
Up to 1 years after CAR-T infusion
|
|
Duration of remission ,DOR
Time Frame: Up to 1 years after CAR-T infusion
|
The time from CR/CRi and PR to disease relapsed or death due to disease progression after CAR-T infusion
|
Up to 1 years after CAR-T infusion
|
|
Complete response (CR), and complete response with incomplete hematologic recovery (CRi)
Time Frame: Up to 12 weeks after CAR-T infusion
|
The proportion of patients with CR (complete response) /CRi (complete response with incomplete blood cell recovery) and PR (partial response).
|
Up to 12 weeks after CAR-T infusion
|
|
Leukemia-Free Survival, LFS
Time Frame: Up to 2 years after Treatment
|
The time from CAR-T infusion torecurrence or metastasis
|
Up to 2 years after Treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: He Huang, MD, First affiliated Hospital of Zhejiang University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TXB2024025
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.